191 related articles for article (PubMed ID: 16872575)
1. A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation.
Callaway JC; Grob CS; McKenna DJ; Nichols DE; Shulgin A; Tupper KW
J Anal Toxicol; 2006; 30(6):406-7; author reply 407. PubMed ID: 16872575
[No Abstract] [Full Text] [Related]
2. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation.
Sklerov J; Levine B; Moore KA; King T; Fowler D
J Anal Toxicol; 2005; 29(8):838-41. PubMed ID: 16356341
[TBL] [Abstract][Full Text] [Related]
3. Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.
Heise CW; Brooks DE
J Med Toxicol; 2017 Sep; 13(3):245-248. PubMed ID: 27896660
[TBL] [Abstract][Full Text] [Related]
4. Syrian rue seeds interacted with acacia tree bark in an herbal stew resulted in N,N-dimethyltryptamine poisoning.
Liu CH; Chu WL; Liao SC; Yang CC; Lin CC
Clin Toxicol (Phila); 2019 Oct; 57(10):867-869. PubMed ID: 30831037
[No Abstract] [Full Text] [Related]
5. Bufo alvarius: a potent hallucinogen of animal origin.
Weil AT; Davis W
J Ethnopharmacol; 1994 Jan; 41(1-2):1-8. PubMed ID: 8170151
[TBL] [Abstract][Full Text] [Related]
6. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
Riga MS; Soria G; Tudela R; Artigas F; Celada P
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
[TBL] [Abstract][Full Text] [Related]
7. 5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous.
Lancelotta R
Hum Psychopharmacol; 2022 May; 37(3):e2839. PubMed ID: 35301754
[No Abstract] [Full Text] [Related]
8. Reply to: 5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous.
James E; Keppler J; Robertshaw TL; Sessa B
Hum Psychopharmacol; 2022 May; 37(3):e2840. PubMed ID: 35301759
[No Abstract] [Full Text] [Related]
9. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
10. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
Rodrigues AV; Almeida FJ; Vieira-Coelho MA
J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
[TBL] [Abstract][Full Text] [Related]
11. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
14. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
15. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
[TBL] [Abstract][Full Text] [Related]
16. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
17. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
18. Ayahuasca for the Treatment of Depression.
Palhano-Fontes F; Soares BL; Galvão-Coelho NL; Arcoverde E; Araujo DB
Curr Top Behav Neurosci; 2022; 56():113-124. PubMed ID: 34761362
[TBL] [Abstract][Full Text] [Related]
19. Ayahuasca: What Healthcare Providers Need to Know.
Goldin D; Salani D
J Addict Nurs; 2021 Apr-Jun 01; 32(2):167-173. PubMed ID: 34060770
[TBL] [Abstract][Full Text] [Related]
20. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
Uthaug MV; Lancelotta R; van Oorsouw K; Kuypers KPC; Mason N; Rak J; Šuláková A; Jurok R; Maryška M; Kuchař M; Páleníček T; Riba J; Ramaekers JG
Psychopharmacology (Berl); 2019 Sep; 236(9):2653-2666. PubMed ID: 30982127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
